112. van den Bosch T, Boichenko A, Leus NG, Ourailidou ME, Wapenaar H, Rotili D, Mai A,
Imhof A, Bischoff R, Haisma HJ, Dekker FJ (2016) The histone acetyltransferase p300
inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.
Biochem Pharmacol 102:130–140. https://doi.org/10.1016/j.bcp.2015.12.010
113. Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi
RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E,
Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston
JW, Weinert BT, Choudhary C, de Vries P, van Drie JH, McElligott D, Kesicki E,
Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD
(2017) Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific
tumours. Nature 550:128–132. https://doi.org/10.1038/nature24028
114. Michaelides MR, Kluge A, Patane M, van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R,
Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA,
Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA (2017) Discovery of spiro
oxazolidinediones as selective, orally bioavailable inhibitors of p300/CBP histone
acetyltransferases. ACS Med Chem Lett 9:28–33. https://doi.org/10.1021/acsmedchemlett.
7b00395
115. Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L,
Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson
CN (2012) Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS
One 7:e45539. https://doi.org/10.1371/journal.pone.0045539
116. Wapenaar H, van den Bosch T, Leus NGJ, van der Wouden PE, Eleftheriadis N, Hermans J,
Hailu GS, Rotili D, Mai A, Domling A, Bischoff R, Haisma HJ, Dekker FJ (2017) The
relevance of Ki calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel
lysine (K) acetyltransferase 8 inhibitor. Eur J Med Chem 136:480–486. https://doi.org/10.
1016/j.ejmech.2017.05.015
122
D. Trisciuoglio and D. Rotili
Imhof A, Bischoff R, Haisma HJ, Dekker FJ (2016) The histone acetyltransferase p300
inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.
Biochem Pharmacol 102:130–140. https://doi.org/10.1016/j.bcp.2015.12.010
113. Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, Hansen TM, Risi
RM, Frey R, Manaves V, Shaw B, Algire M, Hessler P, Lam LT, Uziel T, Faivre E,
Ferguson D, Buchanan FG, Martin RL, Torrent M, Chiang GG, Karukurichi K, Langston
JW, Weinert BT, Choudhary C, de Vries P, van Drie JH, McElligott D, Kesicki E,
Marmorstein R, Sun C, Cole PA, Rosenberg SH, Michaelides MR, Lai A, Bromberg KD
(2017) Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific
tumours. Nature 550:128–132. https://doi.org/10.1038/nature24028
114. Michaelides MR, Kluge A, Patane M, van Drie JH, Wang C, Hansen TM, Risi RM, Mantei R,
Hertel C, Karukurichi K, Nesterov A, McElligott D, de Vries P, Langston JW, Cole PA,
Marmorstein R, Liu H, Lasko L, Bromberg KD, Lai A, Kesicki EA (2017) Discovery of spiro
oxazolidinediones as selective, orally bioavailable inhibitors of p300/CBP histone
acetyltransferases. ACS Med Chem Lett 9:28–33. https://doi.org/10.1021/acsmedchemlett.
7b00395
115. Coffey K, Blackburn TJ, Cook S, Golding BT, Griffin RJ, Hardcastle IR, Hewitt L,
Huberman K, McNeill HV, Newell DR, Roche C, Ryan-Munden CA, Watson A, Robson
CN (2012) Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PLoS
One 7:e45539. https://doi.org/10.1371/journal.pone.0045539
116. Wapenaar H, van den Bosch T, Leus NGJ, van der Wouden PE, Eleftheriadis N, Hermans J,
Hailu GS, Rotili D, Mai A, Domling A, Bischoff R, Haisma HJ, Dekker FJ (2017) The
relevance of Ki calculation for bi-substrate enzymes illustrated by kinetic evaluation of a novel
lysine (K) acetyltransferase 8 inhibitor. Eur J Med Chem 136:480–486. https://doi.org/10.
1016/j.ejmech.2017.05.015
122
D. Trisciuoglio and D. Rotili